Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Receivables - Accured: 2021

Historic Revenue - Other for Autolus Therapeutics (AUTL) over the last 6 years, with Dec 2021 value amounting to $1.5 million.

  • Autolus Therapeutics' Receivables - Accured rose 283.08% to $24.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $24.9 million, marking a year-over-year increase of 283.08%. This contributed to the annual value of $9,631 for FY2021, which is N/A change from last year.
  • Autolus Therapeutics' Revenue - Other amounted to $1.5 million in FY2021, which was up 518.22% from $240,135 recorded in FY2020.
  • Over the past 5 years, Autolus Therapeutics' Revenue - Other peaked at $3.7 million during FY2019, and registered a low of -$1.7 million during FY2017.
  • Its 1-year average for Receivables - Accured is $9,631, with a median of $9,631 in 2021.
  • Per our database at Business Quant, Autolus Therapeutics' Revenue - Other slumped by 198.00% in 2017 and then spiked by 518.22% in 2021.
  • Over the past 5 years, Autolus Therapeutics' Revenue - Other (Yearly) stood at -$1.7 million in 2017, then soared by 211.86% to $1.9 million in 2018, then reached $3.7 million in 2019, then crashed by 93.53% to $240,135 in 2020, then soared by 518.22% to $1.5 million in 2021.